CA2774460C - Inhibition of endosomal toll-like receptor activation - Google Patents

Inhibition of endosomal toll-like receptor activation Download PDF

Info

Publication number
CA2774460C
CA2774460C CA2774460A CA2774460A CA2774460C CA 2774460 C CA2774460 C CA 2774460C CA 2774460 A CA2774460 A CA 2774460A CA 2774460 A CA2774460 A CA 2774460A CA 2774460 C CA2774460 C CA 2774460C
Authority
CA
Canada
Prior art keywords
nucleic acid
tlr9
tlr3
activation
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2774460A
Other languages
English (en)
French (fr)
Other versions
CA2774460A1 (en
Inventor
Bruce A. Sullenger
Jaewoo Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CA2774460A1 publication Critical patent/CA2774460A1/en
Application granted granted Critical
Publication of CA2774460C publication Critical patent/CA2774460C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2774460A 2009-09-16 2010-09-16 Inhibition of endosomal toll-like receptor activation Active CA2774460C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24309009P 2009-09-16 2009-09-16
US61/243,090 2009-09-16
PCT/US2010/002516 WO2011034583A2 (en) 2009-09-16 2010-09-16 Inhibition of endosomal toll-like receptor activation

Publications (2)

Publication Number Publication Date
CA2774460A1 CA2774460A1 (en) 2011-03-24
CA2774460C true CA2774460C (en) 2016-08-09

Family

ID=43759220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2774460A Active CA2774460C (en) 2009-09-16 2010-09-16 Inhibition of endosomal toll-like receptor activation

Country Status (6)

Country Link
US (3) US9468650B2 (enExample)
EP (1) EP2477641B1 (enExample)
CN (1) CN102639142A (enExample)
CA (1) CA2774460C (enExample)
IN (1) IN2012DN02345A (enExample)
WO (1) WO2011034583A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4249913A1 (en) * 2022-03-22 2023-09-27 Centre Hospitalier Universitaire de Nîmes Toll-like-receptor 3 inhibitor for preventing and/or treating disorders in patients with a personal history of venous thromboembolism (vte)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682580A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
IN2012DN02345A (enExample) 2009-09-16 2015-08-21 Univ Duke
WO2012151575A2 (en) 2011-05-05 2012-11-08 Duke University A method of controlling coagulation
WO2014169043A1 (en) * 2013-04-09 2014-10-16 Duke University Anti-inflammatory agents and methods of using the same
WO2015161094A1 (en) 2014-04-16 2015-10-22 Duke University Electrospun cationic nanofibers and methods of making and using the same
US12514872B2 (en) 2015-11-04 2026-01-06 Duke University Polycationic polymers for use in treating and detecting cancer
EP3512526A4 (en) 2016-09-16 2020-05-27 Duke University VON WILLEBRAND FACTOR (VWF) TARGETING AGENTS AND METHODS OF USE
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
JP7231229B2 (ja) 2017-03-23 2023-03-01 デューク ユニバーシティ 細胞外アプタマー染色のアンチドート媒介性解除
CN111182925A (zh) * 2017-05-30 2020-05-19 纽约市哥伦比亚大学理事会 阳离子核酸清除剂及其用途
US11713464B2 (en) 2017-09-08 2023-08-01 Duke University Nucleolin-targeting aptamers and methods of using the same
WO2021016924A1 (zh) * 2019-07-31 2021-02-04 中山大学 可用于治疗银屑病的阳离子聚合物及颗粒

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919761A (en) 1992-08-14 1999-07-06 The Board Of Regents Of The University Of Michigan Peptides for heparin and low molecular weight heparin anticoagulation reversal
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
AU9066001A (en) 2000-09-08 2002-03-22 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2002053185A2 (en) 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
RU2003129062A (ru) 2001-03-08 2005-04-10 Мерк Патент ГмбХ (DE) Модифицированный протамин с уменьшенной иммуногенностью
PT2070939E (pt) 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
JP2005527639A (ja) 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20030180250A1 (en) 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
BR0315198A (pt) 2002-10-09 2005-08-30 Insert Therapeutics Inc Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
EP1649019A2 (en) 2003-07-15 2006-04-26 California Institute Of Technology Improved inhibitor nucleic acids
CN1980947B (zh) 2004-04-22 2013-01-30 雷加多生物科学公司 改良的凝血因子调节物
US8080245B2 (en) * 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
GB0422877D0 (en) * 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
PL1866414T3 (pl) 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
US7611835B2 (en) 2005-09-30 2009-11-03 Battelle Memorial Institute Process for preparing multilayer enzyme coating on a fiber
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
JP2009538325A (ja) 2006-05-26 2009-11-05 リガド・バイオサイエンシーズ・インコーポレーテツド Ｒｅｇ１抗凝固系の投与
EP2035041B1 (en) * 2006-06-30 2020-01-08 Syntab Therapeutics GmbH Conjugates for innate immunotherapy of cancer
US20110118187A1 (en) 2006-10-19 2011-05-19 Duke University Reversible platelet inhibition
WO2008063157A2 (en) 2006-10-25 2008-05-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A nanoparticle-based anticoagulant
CN101657213B (zh) * 2007-02-15 2014-02-26 曼康公司 用于增强t细胞应答的方法
CA2682580A1 (en) * 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
CN101808730A (zh) 2007-09-27 2010-08-18 Sca卫生用品公司 粘土连接的聚合物凝胶
WO2009064767A2 (en) 2007-11-12 2009-05-22 Massachusetts Institute Of Technology Bactericidal nanofibers, and methods of use thereof
WO2010020008A1 (en) 2008-08-22 2010-02-25 Polymers Crc Limited Polymer coatings
US8992991B2 (en) 2009-05-15 2015-03-31 The Johns Hopkins University Multicomponent degradable cationic polymers
IN2012DN02345A (enExample) 2009-09-16 2015-08-21 Univ Duke
WO2012088059A2 (en) 2010-12-20 2012-06-28 Virginia Commonwealth University A facile method for crosslinking and incorporating bioactive molecules into electrospun fiber scaffolds
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4249913A1 (en) * 2022-03-22 2023-09-27 Centre Hospitalier Universitaire de Nîmes Toll-like-receptor 3 inhibitor for preventing and/or treating disorders in patients with a personal history of venous thromboembolism (vte)

Also Published As

Publication number Publication date
CA2774460A1 (en) 2011-03-24
US20170095503A1 (en) 2017-04-06
US9468650B2 (en) 2016-10-18
EP2477641A2 (en) 2012-07-25
EP2477641A4 (en) 2013-08-07
WO2011034583A2 (en) 2011-03-24
CN102639142A (zh) 2012-08-15
US20120183564A1 (en) 2012-07-19
EP2477641B1 (en) 2024-03-27
US20230248805A1 (en) 2023-08-10
US11617779B2 (en) 2023-04-04
IN2012DN02345A (enExample) 2015-08-21
WO2011034583A3 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
US20230248805A1 (en) Inhibition of endosomal toll-like receptor activation
US20220211878A1 (en) Cross-linked polymer modified nanoparticles
US12447464B2 (en) Polycationic microfibers and methods of using the same
Lee et al. Nucleic acid-binding polymers as anti-inflammatory agents
Toy et al. TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination
EP2139992A1 (en) A method of modulating the activity of a nucleic acid molecule
HRP20160136T1 (hr) Peptidno posredovana ne-kovalentna isporuka aktivnih sredstava kroz krvno moždanu barijeru
US20100130425A1 (en) Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
CN107412260A (zh) cGAS-STING通路激活剂及其用途
JP2010535479A (ja) Ｓｄｆ−１結合核酸およびその使用
CN105377305A (zh) 靶向脂肪细胞的非病毒基因递送体系
KR20110083919A (ko) 복합 유전자를 표적하는 ｓｉＲＮＡ 다중 접합체 및 이의 제조방법
US10111898B2 (en) Anti-tumor compositions and methods
US20180333461A1 (en) Methods and compositions for treating or preventing flavivirus infections
JP2020172534A (ja) 合成脳浸透遺伝子ベクターの操作
US20200171167A1 (en) Cationic nucleic acid scavenger and uses thereof
Chan et al. Synthesis and characterization of PEGylated toll like receptor 7 ligands
Song et al. Mechanistic investigation of HMGB1 in an in vitro model of the trigeminovascular system under migraine-like conditions
JP7193083B2 (ja) エクソソームの遺伝子機能を抑制することができる複合体、がんの増殖及び／又は転移抑制剤
RU2681213C2 (ru) Ингибиторы метастазирования
WO2017159835A1 (ja) 形質細胞性腫瘍治療剤
US11613756B2 (en) Compositions and methods for differential induction of cell death and interferon expression
US12427183B2 (en) Methods of treating cancer, infectious disease, and autoimmune disease using chemokines
Petkova Gene therapy in combination with an approach targeting the tumour microenvironment in glioblastoma
Oza Large Peritoneal Macrophage Tropism towards Acute Injury and its Potential for the Treatment of Acetaminophen-Induced Liver Toxicity

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240906

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240906

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240906

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251212

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260427

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713